Back to Newsroom
Back to Newsroom

Lawsuits Filed Against Vrt, Abbv And Ibm - Jakubowitz Law Pursues Shareholders Claims

Thursday, 19 May 2022 03:20 PM

Jakubowitz Law

Topic:
Lawsuits

NEW YORK, NY / ACCESSWIRE / May 19, 2022 / Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies who purchased shares within the class periods listed below. Shareholders interested in representing the class of wronged shareholders have until the lead plaintiff deadline to petition the court. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. For more details and to speak with our firm without cost or obligation, follow the links below.

Vertiv Holdings Co (NYSE:VRT)

CONTACT JAKUBOWITZ ABOUT VRT:
https://claimyourloss.com/securities/vertiv-holdings-co-loss-submission-form/?id=27486&from=1

This lawsuit is on behalf of persons and entities that: (a) purchased or otherwise acquired Vertiv securities between February 24, 2021, and February 23, 2022, inclusive; and/or (b) purchased Vertiv shares in or traceable to the Company's secondary public offering of Class A common stock conducted on or around November 4, 2021.

Lead Plaintiff Deadline : May 23, 2022

The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) the Company could not adequately respond to supply chain issues and inflation by increasing its prices; (2) as a result of the increasing costs, Vertiv's earnings would be adversely impacted; and (3) as a result of the foregoing, defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

AbbVie Inc. (NYSE:ABBV)

CONTACT JAKUBOWITZ ABOUT ABBV:
https://claimyourloss.com/securities/abbvie-inc-loss-submission-form/?id=27486&from=1

Class Period : April 30, 2021 - August 31, 2021

Lead Plaintiff Deadline : June 6, 2022

The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) safety concerns about Pfizer Inc.'s drug Xeljanz extended to Abbvie's drug Rinvoq and to other Janus kinase enzyme inhibitor drugs; (2) as a result, it was likely that the U.S. Food and Drug Administration would require additional safety warnings for Rinvoq and would delay the approval of additional treatment indications for Rinvoq; and (3) therefore, defendants' statements about the Company's business, operations, and prospects lacked a reasonable basis.

International Business Machines Corporation (NYSE:IBM)

CONTACT JAKUBOWITZ ABOUT IBM:
https://claimyourloss.com/securities/international-business-machines-corporation-loss-submission-form/?id=27486&from=1

Class Period : April 4, 2017 - October 20, 2021

Lead Plaintiff Deadline : June 6, 2022

The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) Strategic Imperatives Revenue and growth, CAMSS and CAMSS Components' revenue and growth, and the Company's Segments' revenue and growth were artificially inflated as a result of the wrongful reclassification of revenues from non-strategic to strategic to make those revenues eligible for treatment as Strategic Imperatives Revenue; (ii) the Company's present success and positive future growth prospects concerning its Strategic Imperative business strategy were being fueled by the wrongful reclassification of revenues from non-strategic to strategic to make those revenues eligible for treatment as Strategic Imperative Revenue and, as a result (iii) the Company misled the market by portraying the Company's Strategic Imperative's financial performance and future prospects more favorable than they actually were as a result of the wrongful reclassification of revenues from non-strategic to strategic to make those revenues eligible for treatment as Strategic Imperatives.

Jakubowitz Law, Thursday, May 19, 2022, Press release picture

Jakubowitz Law is vigorous in pursuit of justice for shareholders who have been the victim of securities fraud. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
JAKUBOWITZ LAW
1140 Avenue of the Americas
9th Floor
New York, New York 10036
T: (212) 867-4490
F: (212) 537-5887

SOURCE: Jakubowitz Law

Topic:
Lawsuits
Back to newsroom
Back to Newsroom

Contact Us Today


If you have questions or want to learn more about our products, our team’s here to help!

Share by: